Research ExplorerPublicationsLithium-induced nephropathies.

Lithium-induced nephropathies.

Standard

Lithium-induced nephropathies. / Raedler, Thomas J; Wiedemann, Klaus.

In: PSYCHOPHARMACOL BULL, Vol. 40, No. 2, 2, 2007, p. 134-149.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Raedler, TJ & Wiedemann, K 2007, 'Lithium-induced nephropathies.', PSYCHOPHARMACOL BULL, vol. 40, no. 2, 2, pp. 134-149. <http://www.ncbi.nlm.nih.gov/pubmed/17514192?dopt=Citation>

APA

Raedler, T. J., & Wiedemann, K. (2007). Lithium-induced nephropathies. PSYCHOPHARMACOL BULL, 40(2), 134-149. [2]. http://www.ncbi.nlm.nih.gov/pubmed/17514192?dopt=Citation

Vancouver

Raedler TJ, Wiedemann K. Lithium-induced nephropathies. PSYCHOPHARMACOL BULL. 2007;40(2):134-149. 2.

Bibtex

@article{673c49b5a5cc47f2bc0d1aecf870b06e,
title = "Lithium-induced nephropathies.",
abstract = "Lithium, an alkali metal, remains the gold-standard of the pharmacological treatment of bipolar disorder. Over the past decades, the potential of lithium to cause renal damage has been an issue of debate. Polyuria, polydipsia, and, to a lesser degree, nephrogenic diabetes insipidus are frequently observed under treatment with lithium. The glomerular filtration rate (GFR) decreases progressively in a smaller proportion of subjects after several years of treatment with lithium. An even smaller number of patients continue to develop renal insufficiency, ultimately leading to hemodialysis in a small minority of subjects exposed to lithium. So far, no tests exist to identify subjects at risk of lithium-induced nephropathy at an early stage. Therefore, regular monitoring of creatinine and creatinine clearance are recommended in all subjects taking lithium.",
author = "Raedler, {Thomas J} and Klaus Wiedemann",
year = "2007",
language = "Deutsch",
volume = "40",
pages = "134--149",
number = "2",

}

RIS

TY - JOUR

T1 - Lithium-induced nephropathies.

AU - Raedler, Thomas J

AU - Wiedemann, Klaus

PY - 2007

Y1 - 2007

N2 - Lithium, an alkali metal, remains the gold-standard of the pharmacological treatment of bipolar disorder. Over the past decades, the potential of lithium to cause renal damage has been an issue of debate. Polyuria, polydipsia, and, to a lesser degree, nephrogenic diabetes insipidus are frequently observed under treatment with lithium. The glomerular filtration rate (GFR) decreases progressively in a smaller proportion of subjects after several years of treatment with lithium. An even smaller number of patients continue to develop renal insufficiency, ultimately leading to hemodialysis in a small minority of subjects exposed to lithium. So far, no tests exist to identify subjects at risk of lithium-induced nephropathy at an early stage. Therefore, regular monitoring of creatinine and creatinine clearance are recommended in all subjects taking lithium.

AB - Lithium, an alkali metal, remains the gold-standard of the pharmacological treatment of bipolar disorder. Over the past decades, the potential of lithium to cause renal damage has been an issue of debate. Polyuria, polydipsia, and, to a lesser degree, nephrogenic diabetes insipidus are frequently observed under treatment with lithium. The glomerular filtration rate (GFR) decreases progressively in a smaller proportion of subjects after several years of treatment with lithium. An even smaller number of patients continue to develop renal insufficiency, ultimately leading to hemodialysis in a small minority of subjects exposed to lithium. So far, no tests exist to identify subjects at risk of lithium-induced nephropathy at an early stage. Therefore, regular monitoring of creatinine and creatinine clearance are recommended in all subjects taking lithium.

M3 - SCORING: Zeitschriftenaufsatz

VL - 40

SP - 134

EP - 149

IS - 2

M1 - 2

ER -